Related Experiment Video
Updated: Oct 1, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. II.
Abstract:
The effects of the slow Ca++ channel blocker, nifedipine, and ACAT inhibitor, octimibate, on cholesterol-loaded macrophages were compared at the ultrastructural level. The Ca++ antagonist induced the formation of membrane-surrounded "lamellar bodies" originating from lysosomes. The macrophages secreted these lamellar bodies, which were rich in phospholipids and cholesterol, into the culture medium even in the absence of cholesterol acceptors. In contrast, the ACAT inhibitor induced the formation of lamellar bodies originating from lipid droplets, which were also surrounded by membranes. There is strong evidence that these latter membranes were newly synthesized at the margin of the lipid droplets by the endoplasmic reticulum. The lamellar bodies descending from lipid droplets after ACAT inhibitor treatment were not secreted by the cells. They were stored in the cytoplasmic compartment in the absence of high density lipoproteins (HDL). When HDL were added to the medium, the lamellar bodies specifically interacted with endosomes containing the internalized HDL particles and disappeared concomitantly with an enhanced HDL-mediated cholesterol efflux. From the biochemical data in the accompanying article and the morphological data here, we conclude that macrophages release cholesterol by two major pathways: 1) an HDL-independent secretion of lamellar bodies containing cholesterol, which originate from lysosomes, and 2) an HDL-dependent release of cholesterol via the formation of lamellar bodies descending from lipid droplets, which intracellularly fuse with HDL-containing endosomes. The cholesterol-enriched HDL are then secreted as intact lipoproteins.
Insights
This study reveals two pathways for cholesterol release from macrophages: one independent of HDL involving lysosomes, and another dependent on HDL via lipid droplets and endosomes.
Area of Science:
- Cell Biology
- Macrophage Biology
- Lipid Metabolism
Background:
- Cholesterol accumulation in macrophages contributes to atherosclerosis.
- Understanding cholesterol efflux mechanisms is crucial for cardiovascular disease research.
Purpose of the Study:
- To compare the ultrastructural effects of nifedipine (a Ca++ channel blocker) and octimibate (an ACAT inhibitor) on cholesterol-loaded macrophages.
- To elucidate the distinct pathways of cholesterol release from macrophages.
Main Methods:
- Ultrastructural analysis of cholesterol-loaded macrophages treated with nifedipine and octimibate.
- Observation of lamellar body formation, origin, and secretion.
- Investigation of high-density lipoprotein (HDL) interaction with cellular components.
Main Results:
- Nifedipine induced lysosome-derived lamellar bodies, rich in cholesterol and phospholipids, which were secreted independently of HDL.
- Octimibate treatment led to the formation of lipid droplet-derived lamellar bodies, not secreted but stored intracellularly.
- These octimibate-induced lamellar bodies interacted with HDL-containing endosomes, promoting HDL-mediated cholesterol efflux.
Conclusions:
- Macrophages release cholesterol via two distinct pathways: HDL-independent secretion of lysosome-derived lamellar bodies and HDL-dependent release involving lipid droplet-derived lamellar bodies and HDL-containing endosomes.
- These findings provide morphological evidence supporting distinct mechanisms of cellular cholesterol transport and secretion.
Related Concept Videos
Receptor-mediated Endocytosis
Inflammation
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

